Oncology development
PIKALO-2: Tersolisib, Mutant-Selective PI3Kα Inhibition and Breast Cancer Trial Readiness
Explore Lilly's recruiting PIKALO-2 tersolisib breast cancer trial, mutant-selective PI3Kα rationale, evidence limits and oncology site-readiness priorities.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
Lilly lists PIKALO-2 (NCT07174336) as recruiting. Its Phase 3 portion evaluates the addition of investigational tersolisib to endocrine therapy and a CDK4/6 inhibitor, compared with placebo plus that treatment backbone, in adults with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who have received no prior systemic treatment for advanced disease. The study also includes a Phase 2 dose-optimization portion; eligibility differs between the two parts. [1, 2]
Tersolisib, previously called STX-478 and also identified as LY4064809, is an allosteric PI3Kα inhibitor designed to preferentially target mutant forms of the enzyme. Preclinical research supports the rationale for separating antitumor activity from effects on normal metabolic signaling. Those laboratory and animal findings do not establish the benefit-risk profile of a first-line combination in patients. [3]
PI3K-directed combinations already have a clinical role. FDA approved inavolisib with palbociclib and fulvestrant in 2024 for a defined endocrine-resistant, PIK3CA-mutated advanced breast cancer population following recurrence on or after adjuvant endocrine therapy. PIKALO-2 is not a head-to-head comparison with that regimen, and its recruiting announcement does not support claims of superiority. [4]
Lilly's trial materials retain diabetes-related exclusions and metabolic eligibility requirements. Mutant selectivity should therefore not be treated as permission to relax glucose review, safety surveillance or protocol-specific medical assessment. Full eligibility and local recruitment availability should be confirmed through the study team. Sources and status checked November 5, 2026. [1, 2]
What this means for trial teams
The mutation is only the start. Lampgen's interpretation is that a biomarker-defined study still needs a reliable pathway from referral to testing, eligibility confirmation, treatment and follow-up. Each handoff needs an owner and a traceable record.
For biomarker documentation, teams should establish which assay and report support eligibility, how specimen adequacy is checked, and who resolves uncertain or conflicting findings. A potential molecular match is the beginning of eligibility assessment. It does not guarantee that someone qualifies or that an enrolling site can accept them.
For combination treatment, readiness includes protocol-specific training on dose interruptions, adverse-event documentation, concomitant medications and the timing of required assessments. Metabolic screening deserves explicit attention. Investigators and medical teams make clinical decisions; CRAs support source verification, documentation, compliance and timely escalation. These are our operational priorities, not a substitute for the protocol.
For patient access, trial teams should review test turnaround, referral delays, travel, time away from work and communication needs. Tracking why potential participants do not reach enrollment can reveal practical barriers. Support arrangements should be confirmed before they are offered. An enrolling study creates an opportunity only when the pathway is feasible for the person considering it.
The evidence questions extend beyond whether the combination delays progression. Tolerability, dose modifications, discontinuations and patient experience will matter when interpreting its practical value. If the study demonstrates a favorable benefit-risk profile, it could inform future first-line treatment choices in its studied population. The recruiting announcement cannot establish that outcome.
For sponsors and CROs, the staffing implication is specific: evaluate oncology CRA experience against biomarker-dependent eligibility, combination-treatment monitoring, safety reconciliation and sustained follow-up. Lampgen Clinical Research provides oncology CRA staffing and clinical-operations support. Relevant experience should be demonstrated against the assignment's actual demands.
This article is independent industry analysis. The visual is a conceptual AI-generated scene, not a study site or participant. For current study details and locations, consult Lilly's trial page and ClinicalTrials.gov.